EXEL
NASDAQ · Biotechnology
Exelixis Inc
$72.09
+2.52 (+3.62%)
Performance
1D
—
1W
+2.79%
1M
+20.51%
3M
+40.44%
6M
+40.55%
1Y
+74.09%
YTD
+65.42%
Open$70.45
Previous Close$69.57
Day High$72.16
Day Low$69.39
52W High$73.69
52W Low$38.19
Volume—
Avg Volume3.16M
Market Cap16.67B
P/E Ratio18.84
EPS$3.34
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$60.92
Above
SMA 200
$51.57
Above
RSI (14)
70.6
Overbought
Trend
Golden Cross
Bullish
Analyst Ratings
Hold
24 analysts
Price Target
+61.0% upside
Current
$72.09
$72.09
Target
$116.10
$116.10
$78.53
$116.10 avg
$123.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.97B | 1.75B | 2.68B |
| Net Income | 665.40M | 530.29M | -77,688,294 |
| Profit Margin | 33.7% | 32.0% | -2.9% |
| EBITDA | 766.32M | 644.65M | -84,355,918 |
| Free Cash Flow | — | — | -70,301,392 |
| Rev Growth | +12.9% | +12.9% | +9.9% |
| Debt/Equity | — | — | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $293.30 | +0.68% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $463.45 | +0.66% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $169.25 | +1.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $549.39 | +0.42% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $922.99 | +2.06% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.52 | +0.37% | 7.7 | 20.98B |